Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...

Please provide your email address to receive an email when new articles are posted on . The procedure helped lower IOP, but complete success was rare. The intervention is “additive and not ...

While Both iStent and iStent inject Showed Significant IOP and Medication Reduction in Combo-Cataract Procedures at 1 Year Postoperative, iStent inject Achieved Greater Absolute IOP Declines with 93% ...

Over 2.2 million Americans suffer from glaucoma — now a new procedure may relieve symptoms. Glaucoma is a disease in which there is a buildup of pressure behind the eye. The pressure often damages the ...

To evaluate the safety, efficacy, and the cost of combined phacoemulsification and single iStent insertion in open angle glaucoma (OAG) at 3-years follow-up. This was a prospective, uncontrolled, ...

Marcia Opstad and her husband, Greg, left their Cloquet home at 5:30 a.m. last Tuesday, headed for the Lakewalk Surgery Center. When they returned 4½ hours later, Marcia had a new lens in her right ...

Glaucoma is a group of diseases that causes damage to an individual’s optic nerve, primarily from increased intraocular pressure. This increased pressure or ocular hypertension is usually caused by ...

Glaukos said today that the Japanese Ministry of Health, Labor & Welfare approved its iStent device for treating glaucoma. Orange County, California-based Glaukos announced that the approval indicates ...

MILWAUKEE — Glaucoma is a common and chronic disease that affects a person's vision. There are several ways of treating glaucoma, but there's an innovative new option for patients that reduces eye ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, ...